Mesothelioma - 61 Studies Found

Completed : Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
: Pleural Biphasic Mesothelioma
: 2025-08-06
: Given IV
Completed : MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
: Unresectable Pleural Mesothelioma
: 2025-08-06
: MEDI5752: Administered as IV infusion
Completed : Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
: Malignant Pleural Mesothelioma
: 2025-08-06
: At baseline (before any treatment is administered) and at three points after treatment (1, 3, and 6 months).A breath sample from each patient wi
NOT_YET_RECRUITING : Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
: Mesothelioma
: 2025-08-06
: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.
NOT_YET_RECRUITING : OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
: Malignant Pleural Mesothelioma
: 2025-08-06
: OT-101 in combination of pembrolizumab
COMPLETED : Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma
: Mesothelioma
: 2025-08-06
: Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the in
COMPLETED : Nivolumab with Chemotherapy in Pleural Mesothelioma After Surgery
: Pleural Mesothelioma Malignant
: 2025-08-06
: chemotherapy iv
COMPLETED : Autologous Dendritic Cell Vaccination in Mesothelioma
: Malignant Pleural Mesothelioma
: 2025-08-06
: A. Chemoimmunotherapy:
  • four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be adm
    		•
    COMPLETED : Poly-ICLC (Hiltonol�) Vaccine In Malignant Pleural Mesothelioma
    : Malignant Pleural Mesothelioma
    : 2025-08-06
    : See previous Safety group description
    COMPLETED : Poly-ICLC (Hiltonol�) Vaccine In Malignant Pleural Mesothelioma
    : Malignant Pleural Mesothelioma
    : 2025-08-06
    : See previous Safety group description
    <<< Previous | Next >>>